Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.67 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.67 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.67 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458224 | 1.00 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL15069989 | 0.91 | PIK3CD (0.55) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL470063 | 0.90 | PIK3CD (0.54) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL661037 | 0.90 | PIK3CA (0.57) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL463381 | 0.90 | PIK3CA (0.57) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL21087321 | 0.83 | PIK3CA (0.49) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL457631 | 0.82 | PIK3CA (0.48) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL17255826 | 0.81 | PIK3CA (0.48) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL173490 | 0.81 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 | |
| SCHEMBL29394358 | 0.81 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CGPIK3CBPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237073-A1 | Novel Polymorphs and Salts | GLAXO GROUP LTD (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9353098-B2 | Polymorphs and salts | GLAXO GROUP LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-20150299177-A1 | Novel Polymorphs and Salts | GLAXO GROUP LIMITED (GB) | 2015-10-22 | — | — | US | disclosed |
| US-9102668-B2 | Polymorphs and salts | GLAXO GROUP LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| EP-2614058-B1 | POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-07-08 | — | — | EP | disclosed |
| US-20140256721-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-8735390-B2 | Polymorphs and salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-05-27 | — | — | US | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20130165441-A1 | Novel Polymorphs and Salts | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165441-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CG 290/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CA 2691/4885PIK3CG 2718/4885 |
| US-20160237073-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CG 290/4885 |
| US-20150299177-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CG 290/4885 |
| US-20140256721-A1 | Novel Polymorphs and Salts | PRKDC, PRKACA, MAP3K20 | PIK3CD 153/4885PIK3CA 133/4885PIK3CG 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.